

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>MYERS ROBERT L</b>			2. Issuer Name and Ticker or Trading Symbol <b>Predictive Oncology Inc. [ POAI ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>Chief Financial Officer</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>09/04/2020</b>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
2915 COMMERS DRIVE, SUITE 900			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)								
<b>EAGAN</b>	<b>MN</b>	<b>55121</b>						
(City)	(State)	(Zip)						

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								77 <sup>(4)</sup>	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Options	\$1,500	09/04/2020		D <sup>(1)</sup>			53	(2)	08/13/2022	Common Stock	53	\$0	0	D	
Stock Options (Right to buy)	\$1.54	09/04/2020		A <sup>(1)</sup>		53		(2)	08/13/2022	Common Stock	53	\$0	53	D	
Stock Options (Right to buy)	\$1,481.25	09/04/2020		D <sup>(1)</sup>			42	(2)	08/29/2023	Common Stock	42	\$0	0	D	
Stock Options (Right to buy)	\$1.54	09/04/2020		A <sup>(1)</sup>		42		(2)	08/29/2023	Common Stock	42	\$0	42	D	
Stock Options (Right to buy)	\$4,312.5	09/04/2020		D <sup>(1)</sup>			14	(2)	03/07/2024	Common Stock	14	\$0	0	D	
Stock Options (Right to buy)	\$1.54	09/04/2020		A <sup>(1)</sup>		14		(2)	03/07/2024	Common Stock	14	\$0	14	D	
Stock Options (Right to buy)	\$41,975	09/04/2020		D <sup>(1)</sup>			357	(2)	09/16/2026	Common Stock	357	\$0	0	D	
Stock Options (Right to buy)	\$1.54	09/04/2020		A <sup>(1)</sup>		357		(2)	09/16/2026	Common Stock	357	\$0	357	D	
Stock Options (Right to buy)	\$14.7	09/04/2020		D <sup>(1)</sup>			30,411	(2)	06/22/2027	Common Stock	30,411	\$0	0	D	
Stock Options (Right to buy)	\$1.54	09/04/2020		A <sup>(1)</sup>		30,411		(2)	06/22/2027	Common Stock	30,411	\$0	30,411	D	
Stock Options (Right to buy)	\$7.48	09/04/2020		D <sup>(1)</sup>			16,600	(3)	04/04/2029	Common Stock	16,600	\$0	0	D	
Stock Options (right to buy)	\$1.54	09/04/2020		A <sup>(1)</sup>		16,600		(3)	04/04/2029	Common Stock	16,600	\$0	16,600	D	

**Explanation of Responses:**

- All transactions reported on this form involve the repricing of stock options with an exercise price greater than \$1.54 to an exercise price of \$1.54, as approved by shareholders at the 2020 annual meeting, with certification of the shareholder vote as of September 4, 2020.
- Currently exercisable.

3. 12,450 shares are currently vested; 2,075 shares vest on each of 10/4/2020 and 1/4/2021.

4. Share ownership totals have been adjusted to reflect a 1 for 10 reverse stock split effected by the issuer on October 29, 2019.

/s/ Bob Myers

09/09/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**